Discover open access scientific publications

Search, annotate, share and cite publications

Publications by K. Kelly

P3.13-26 Outcomes of Patients With Metastatic Lung Cancer Presented in a Multidisciplinary Molecular Tumor Board

Journal of Thoracic Oncology

English

P1.16-47 Adjuvant Targeted Therapy Following Standard Adjuvant Therapy for Resected NSCLC: An Initial Report From ALCHEMIST (Alliance A151216)

Journal of Thoracic Oncology

English

OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results From SWOG S1403

Journal of Thoracic Oncology

English

P1.04-09 Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC With Progression on Prior EGFR-TKI

Journal of Thoracic Oncology

English

OA06.01 Case-Series Study in Ever- And Never-Smoking Females and Males With NSCLC: Exposures, Tumor Factors, Biology and Survival (SWOG S0424)

Journal of Thoracic Oncology

English

MS18.02 Treatment of Elderly Patients With SCLC

Journal of Thoracic Oncology

English

Investigation of Metabolomic Blood Biomarkers for Detection of Adenocarcinoma Lung Cancer

Cancer Epidemiology Biomarkers and Prevention

English

Qualitative Equivalence Between a Paper and Electronic Tablet Version of the Womac®Nrs3.1 and Patient Global Assessment

English

Inclusion of a Pediatric Perspective Into Recommendations for the Initial Evaluation and Staging of Hodgkin Lymphoma: A Call to Action From the International Search Working Group

Hematological Oncology

English

Dose Finding Study to Assess Safety, Pk and Efficacy of Fimepinostat (Cudc-907) With Venetoclax or Rituximab Plus Bendamustine in Patients With Relapsed/Refractory Lymphoma

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by K. Kelly

P3.13-26 Outcomes of Patients With Metastatic Lung Cancer Presented in a Multidisciplinary Molecular Tumor Board

P1.16-47 Adjuvant Targeted Therapy Following Standard Adjuvant Therapy for Resected NSCLC: An Initial Report From ALCHEMIST (Alliance A151216)

OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results From SWOG S1403

P1.04-09 Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC With Progression on Prior EGFR-TKI

OA06.01 Case-Series Study in Ever- And Never-Smoking Females and Males With NSCLC: Exposures, Tumor Factors, Biology and Survival (SWOG S0424)

MS18.02 Treatment of Elderly Patients With SCLC

Investigation of Metabolomic Blood Biomarkers for Detection of Adenocarcinoma Lung Cancer

Qualitative Equivalence Between a Paper and Electronic Tablet Version of the Womac®Nrs3.1 and Patient Global Assessment

Inclusion of a Pediatric Perspective Into Recommendations for the Initial Evaluation and Staging of Hodgkin Lymphoma: A Call to Action From the International Search Working Group

Dose Finding Study to Assess Safety, Pk and Efficacy of Fimepinostat (Cudc-907) With Venetoclax or Rituximab Plus Bendamustine in Patients With Relapsed/Refractory Lymphoma